Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products internationally. They offer prescription medicines in areas like cardiovascular, immunology, oncology, ophthalmology, and hematology. The company has agreements with Alnylam Pharmaceuticals and Dawn Health to develop and commercialize inclisiran and Ekiva respectively.
Overview
Strengths
- Return on invested capital has stayed above 15% in 6 of the last 7 years (latest 24.1%), a hallmark of a durable competitive advantage.
- Creates economic value: ROIC of 24.1% against a cost of capital (WACC) of 4.0%, a spread of 20.0 percentage points.
- Shareholder-friendly capital allocation: the share count has shrunk by 3.4% a year over the last three years through buybacks.
- Conservative leverage: net debt is only 1.0x EBITDA.
Weaknesses
- Our discounted cash flow target price (130.99 USD) is 19% below the current price.
Key Financial Data